| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10478502 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(8 years from now) | |
| US8809307 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(8 years from now) | |
| US11679115 | BAUSCH | Topical compositions and methods for treating psoriasis |
Jun, 2036
(12 years from now) | |
| US11648256 | BAUSCH | Topical compositions and methods for treating psoriasis |
Jun, 2036
(12 years from now) | |
| US10426787 | BAUSCH | Topical compositions and methods for treating psoriasis |
Jun, 2036
(12 years from now) | |
| US10251895 | BAUSCH | Topical compositions and methods for treating psoriasis |
Jun, 2036
(12 years from now) | |
Duobrii is owned by Bausch.
Duobrii contains Halobetasol Propionate; Tazarotene.
Duobrii has a total of 6 drug patents out of which 0 drug patents have expired.
Duobrii was authorised for market use on 25 April, 2019.
Duobrii is available in lotion;topical dosage forms.
Duobrii can be used as topical treatment of plaque psoriasis in adults.
The generics of Duobrii are possible to be released after 06 June, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Apr 25, 2022 |
Drugs and Companies using HALOBETASOL PROPIONATE; TAZAROTENE ingredient
Market Authorisation Date: 25 April, 2019
Treatment: Topical treatment of plaque psoriasis in adults
Dosage: LOTION;TOPICAL
DUOBRII family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic